NCT00045110View on ClinicalTrials.gov

Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Adult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaAdult Grade I MeningiomaAdult Grade II MeningiomaAdult Grade III MeningiomaRecurrent Adult Brain Tumor
Interventions
DRUG

erlotinib hydrochloride

given orally

OTHER

laboratory biomarker analysis

correlative studies

OTHER

pharmacological study

correlative studies

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

15232

University of Pittsburgh, Pittsburgh

20814

National Cancer Institute Neuro-Oncology Branch, Bethesda

53792

University of Wisconsin, Madison

75235

University of Texas Southwestern Medical Center, Dallas

90095

University of California Los Angeles, Los Angeles

94115

University of California San Francisco, San Francisco

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00045110 - Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | Biotech Hunter | Biotech Hunter